ArticleGlobal epidemiology2025
Identifying risk factors of post-COVID-19 conditions with machine learning and deep learning algorithms.
Article in Global epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Post-COVID-19 conditions (PCC) affect millions of people in the United States. Early diagnosis and PCC management requires an understanding of the epidemiology and drivers behind PCC in the real world. Methods: We applied multiple machine learning and deep learning models to a large electronic health database of patients with a recent COVID-19 infection in the United States from 2020 to 2022 to quantitatively evaluate progression to newly developed PCC and identify the individual-level risk factors for developing new PCC at 60, 74, 90, and 120 days following initial SARS-CoV-2 infection. Results: Patients with newly developed primary or secondary PCC were older; had higher Charleson comorbidity scores; and were more likely to smoke, have a body mass index ≥30, or have hyperlipidemia or hypertension than those without evidence of newly developed PCC. Three different machine learning models used to evaluate both the full study period and the Omicron era (beginning January 2022) consistently identified age, the Charlson comorbidity score, and healthcare utilization within 30 days of the index COVID-19 infection as the leading risk factors for developing new primary or secondary PCC. The presence of disseminated intravascular coagulation at baseline was among the 10 strongest predictors of newly developed cardiovascular or secondary PCC in the full study period and the Omicron era. Conclusion: Multiple machine learning and deep learning models identified the Charlson comorbidity score, age, and frequency of healthcare utilization, which may help predict the occurrence of new PCC and demonstrated the utility of the models for individualized risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.